{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:39:46Z","timestamp":1766137186847,"version":"3.37.3"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0216327","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T14:08:25Z","timestamp":1557238105000},"page":"e0216327","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of chronic HCV infection with DAAs in Rio de Janeiro\/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-2658","authenticated-orcid":true,"given":"Vanessa D.","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Brand\u00e3o-Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estev\u00e3o P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Guilherme Cor\u00f4a","family":"dos Santos Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia Laura Lewis Ximenez","family":"de Souza Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Campello","family":"do Amaral Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"ref1","unstructured":"WHO. Prevalence of chronically infected people with hepatitis C virus (HCV) worldwide 2018 [cited 2018 15th november]. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c<\/ext-link>."},{"key":"ref2","unstructured":"Minist\u00e9rio da Sa\u00fade (Brasil). Boletim Epidemiol\u00f3gico de Hepatites Virais 2018 [cited 2018 15th november]. http:\/\/www.aids.gov.br\/system\/tdf\/pub\/2018\/65812\/boletim_hepatites_2018_sm_.pdf?file=1&type=node&id=65812&force=1<\/ext-link>."},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"MG Swain","year":"2010","journal-title":"Gastroenterology"},{"key":"ref4","unstructured":"Minist\u00e9rio da Sa\u00fade (Brasil). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es 2015 [cited 2018 July 20th]. http:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/protocolo_clinico_diretrizes_hepatite_co_coinfeccoes.pdf<\/ext-link>."},{"key":"ref5","unstructured":"Minist\u00e9rio da Sa\u00fade (Brasil). Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es 2018. [cited 2018 December 28th]. http:\/\/www.aids.gov.br\/pt-br\/pub\/2017\/protocolo-clinico-e-diretrizes-terapeuticas-para-hepatite-c-e-coinfeccoes<\/ext-link>."},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens","volume":"151","author":"JM Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"E Poveda","year":"2014","journal-title":"Antiviral research"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11904-017-0369-5","article-title":"Resistance to DAAs: When to Look and When It Matters","volume":"14","author":"DL Wyles","year":"2017","journal-title":"Current HIV\/AIDS reports"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/jmv.24527","article-title":"Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals","volume":"88","author":"N Coppola","year":"2016","journal-title":"Journal of medical virology"},{"issue":"3","key":"ref10","first-page":"103","article-title":"Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens","volume":"25","author":"DL Wyles","year":"2017","journal-title":"Topics in antiviral medicine"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12879-017-2817-7","article-title":"Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil","volume":"17","author":"F Malta","year":"2017","journal-title":"BMC infectious diseases"},{"key":"ref12","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5","author":"D Smith","year":"2018","journal-title":"A inhibitors. Hepatology"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil","volume":"16","author":"H Cheinquer","year":"2017","journal-title":"Annals of hepatology"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dku462","article-title":"NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus","volume":"70","author":"A Peres-da-Silva","year":"2015","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3851\/IMP3131","article-title":"Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV","volume":"22","author":"A Peres-da-Silva","year":"2017","journal-title":"Antiviral therapy"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/molbev\/msw054","article-title":"MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets","volume":"33","author":"S Kumar","year":"2016","journal-title":"Molecular biology and evolution"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apsb.2015.09.008","article-title":"Direct anti-HCV agents","volume":"6","author":"X Zhang","year":"2016","journal-title":"Acta pharmaceutica Sinica B"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3350\/cmh.2016.0107","article-title":"Management of direct antiviral agent failures","volume":"22","author":"M Buti","year":"2016","journal-title":"Clinical and molecular hepatology"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"DR Nelson","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1","volume":"373","author":"DL Wyles","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2015.04.019","article-title":"High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013","volume":"63","author":"H Kovari","year":"2015","journal-title":"Journal of hepatology"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir","volume":"151","author":"C Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijid.2016.06.020","article-title":"Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin","volume":"49","author":"SG Parisi","year":"2016","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","author":"F Suzuki","year":"2012","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"DJ Bartels","year":"2013","journal-title":"Journal of virology"},{"issue":"10","key":"ref27","first-page":"1185","article-title":"[Current recommendations for the treatment of chronic hepatitis C]","volume":"52","author":"C Sarrazin","year":"2014","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome","volume":"66","author":"S Zeuzem","year":"2017","journal-title":"Journal of hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients","volume":"10","author":"S Paolucci","year":"2013","journal-title":"Virology journal"},{"issue":"27","key":"ref30","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"GR Foster","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3851\/IMP2763","article-title":"Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1\u20134","volume":"20","author":"AL McCormick","year":"2015","journal-title":"Antiviral therapy"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","article-title":"Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir","volume":"58","author":"F McPhee","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00705-016-3094-2","article-title":"Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV","volume":"162","author":"CF Noble","year":"2017","journal-title":"Archives of virology"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1590\/S0074-02762011000800011","article-title":"Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients","volume":"106","author":"MC Castilho","year":"2011","journal-title":"Memorias do Instituto Oswaldo Cruz"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12985-015-0414-1","article-title":"Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C","volume":"12","author":"A Costantino","year":"2015","journal-title":"Virology journal"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3851\/IMP2091","article-title":"Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor","volume":"17","author":"Z Plaza","year":"2012","journal-title":"Antiviral therapy"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/jac\/dkr385","article-title":"Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV\/HCV co-infected patients","volume":"66","author":"Z Plaza","year":"2011","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3851\/IMP1760","article-title":"Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients","volume":"16","author":"A Trevino","year":"2011","journal-title":"Antiviral therapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0216327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:49:19Z","timestamp":1588963759000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0216327"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0216327","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,5,7]]}}}